GPR18 is a G protein-coupled receptor (GPCR) that is expressed in lymphoid tissues, lung, brain, testis, and ovaries.1 It is coupled to the Gαi/o and Gαq/11 transduction pathways and is activated by the polyunsaturated fatty acid metabolite resolvin D2 (Item No. 10007279) and the endocannabinoid arachidonoyl glycine (NAGly; Item No. 90051). Resolvin D2-induced activation of GPR18 reduces inflammatory pain induced by formalin, carrageenan, and complete Freund’s adjuvant (CFA) in rats and reduces production of pro-inflammatory cytokines in mouse models of cecal ligation and puncture-induced sepsis, ocular infections, and ischemic injury.2,3 NAGly-induced activation of GPR18 lowers intraocular pressure (IOP) in mice in a fatty acid amide hydrolase-dependent manner.4 GPR18 is also overexpressed and constitutively active in patient-derived metastatic melanoma tumor samples.5 Cayman’s GPR18 (C-Term) Polyclonal Antibody can be used for ELISA and immunohistochemistry (IHC) applications. The antibody recognizes the C-terminal region of GPR18 from human samples.WARNING This product is not for human or veterinary use.